Ni/HZSM-5 catalyst preparation by deposition-precipitation. Part 2. Catalytic hydrodeoxygenation reactions of lignin model compounds in organic and aqueous systems

Nickel metal supported on HZSM-5 (zeolite) is a promising catalyst for lignin depolymerization. In this work, the ability of catalysts prepared via deposition-precipitation (DP) to perform hydrodeoxygenation (HDO) on two lignin model compounds in organic and aqueous solvents was evaluated; guaiacol in dodecane and 2-phenoxy-1-phenylethanol (PPE) in aqueous solutions. All Ni/HZSM-5 catalysts were capable of guaiacol HDO into cyclohexane at 523 K. The role of the HZSM-5 acid sites was confirmed by comparison with Ni/SiO2 (inert support) which exhibited incomplete deoxygenation of guaiacol due to the inability to perform the cyclohexanol dehydration step. The catalyst prepared with 15 wt% Ni, a DP time of 16 h, and a calcination temperature of 673 K (Ni(15)/HZSM-5 DP16_Cal673), performed the guaiacol conversion with the greatest selectivity towards HDO products, with an intrinsic rate ratio (HDO rate to conversion rate) of 0.31, and 90% selectivity to cyclohexane. Catalytic activity and selectivity of Ni/HZSM-5 (15 wt%) in aqueous environments (water and 0.1 M NaOH solution) was confirmed using PPE reactions at 523 K. After 30 min reaction time in water, Ni/HZSM-5 exhibited ~100% conversion of PPE, and good yield of the desired products; ethylbenzene and phenol (~35% and 23% of initial carbon, respectively). Ni/HZSM-5 in NaOH solution resulted in significantly higher ring saturation compared to the Ni/HZSM-5 in water or the NaOH solution control

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Estado quimico y composicion de superficies mediante espectroscopia fotoelectrica Caracterizacion Superficial de Solidos

Available from Centro de Informacion y Documentacion Cientifica CINDOC. Joaquin Costa, 22. 28002 Madrid. SPAIN / CINDOC - Centro de Informaciòn y Documentaciòn CientìficaSIGLEESSpai

Termogravimetria en presencia de gases reactivos Caracterizacion Superficial de Solidos

Available from Centro de Informacion y Documentacion Cientifica CINDOC. Joaquin Costa, 22. 28002 Madrid. SPAIN / CINDOC - Centro de Informaciòn y Documentaciòn CientìficaSIGLEESSpai

Immunocompromised patients with acute respiratory distress syndrome : Secondary analysis of the LUNG SAFE database

The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS. Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively ventilated ab initio. Conclusions: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS in these immunocompromised patients. Their management differs from that of immunocompetent patients, particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these patients survive to hospital discharge. Trial registration: ClinicalTrials.gov, NCT02010073. Registered on 12 December 2013

Charged-particle multiplicity fluctuations in Pb–Pb collisions at √ sNN = 2.76 TeV

Measurements of event-by-event fluctuations of charged-particle multiplicities in Pb–Pb collisionsat √sNN = 2.76 TeV using the ALICE detector at the CERN Large Hadron Collider (LHC) are presented in the pseudorapidity range |η| < 0.8 and transverse momentum 0.2 < pT < 2.0 GeV/c. The amplitude of the fluctuations is expressed in terms of the variance normalized by the mean of the multiplicity distribution. The η and pT dependences of the fluctuations and their evolution with respect to collision centrality are investigated. The multiplicity fluctuations tend to decrease from peripheral to central collisions. The results are compared to those obtained from HIJING and AMPT Monte Carlo event generators as well as to experimental data at lower collision energies. Additionally, the measured multiplicity fluctuations are discussed in the context of the isothermal compressibility of the high-density strongly-interacting system formed in central Pb–Pb collisions

First measurements of N-subjettiness in central Pb–Pb collisions at √ sNN = 2.76 TeV

The ALICE Collaboration reports the first fully-corrected measurements of the N-subjettiness observable for track-based jets in heavy-ion collisions. This study is performed using data recorded in pp and Pb–Pb collisions at centre-of-mass energies of √s = 7 TeV and √ sNN = 2.76 TeV, respectively. In particular the ratio of 2-subjettiness to 1-subjettiness, τ2/τ1, which is sensitive to the rate of two-pronged jet substructure, is presented. Energy loss of jets traversing the strongly interacting medium in heavy-ion collisions is expected to change the rate of two-pronged substructure relative to vacuum. The results are presented for jets with a resolution parameter of R = 0.4 and charged jet transverse momentum of 40 ≤ pT,jet ≤ 60 GeV/c, which constitute a larger jet resolution and lower jet transverse momentum interval than previous measurements in heavy-ion collisions. This has been achieved by utilising a semi-inclusive hadron-jet coincidence technique to suppress the larger jet combinatorial background in this kinematic region. No significant modification of the τ2/τ1 observable for track-based jets in Pb–Pb collisions is observed relative to vacuum PYTHIA6 and PYTHIA8 references at the same collision energy. The measurements of τ2/τ1, together with the splitting aperture angle ∆R, are also performed in pp collisions at √s = 7 TeV for inclusive jets. These results are compared with PYTHIA calculations at √s = 7 TeV, in order to validate the model as a vacuum reference for the Pb–Pb centre-of-mass energy. The PYTHIA references for τ2/τ1 are shifted to larger values compared to the measurement in pp collisions. This hints at a reduction in the rate of two-pronged jets in Pb–Pb collisions compared to pp collisions

KS0\mathrm {K_S}^{0}- and (anti-)Λ\Lambda -hadron correlations in pp collisions at s=13{\sqrt{s}} = 13 TeV

International audienceTwo-particle Azimuthal correlations are measured with the ALICE apparatus in pp collisions at $\sqrt{s} = 13$ TeV to explore strangeness- and multiplicity-related effects in the fragmentation of jets and the transition regime between bulk and hard production, probed with the condition that a strange meson ($\mathrm {K_S}^{0}$) or baryon ($\Lambda$) with transverse momentum $p_{\mathrm T} >3$ GeV/$c$ is produced. Azimuthal correlations between kaons or $\Lambda$ hyperons with other hadrons are presented at midrapidity for a broad range of the trigger ($3< p_\mathrm {T}^\mathrm {trigg} < 20$ GeV/$c$) and associated particle $p_{\mathrm T}$ (1 GeV/$c< p_\mathrm {T}^\mathrm {assoc} < p_\mathrm {T}^\mathrm {trigg}$), for minimum-bias events and as a function of the event multiplicity. The near- and away-side peak yields are compared for the case of either $\mathrm {K_S}^{0}$ or $\Lambda$(${\overline{\Lambda }}$) being the trigger particle with that of inclusive hadrons (a sample dominated by pions). In addition, the measurements are compared with predictions from PYTHIA 8 and EPOS LHC event generators